Mechanistic comparison of darapladib [Supplementary Concept] and same based on molecular target overlap from BindingDB and ChEMBL binding affinity data.
2
Shared Targets
9%
Jaccard Similarity
10%
IDF-Weighted Similarity
Jaccard measures raw target overlap. IDF-weighted downweights promiscuous hub targets (e.g. CYP enzymes) that bind many compounds non-specifically.
darapladib and same share 2 molecular targets based on binding affinity data from BindingDB (Kd/IC50 ≤ 10 µM) and ChEMBL. A Jaccard index of 0.091 means 9% of the combined target set is bound by both compounds. The IDF-weighted score of 0.102 accounts for non-specific binding to metabolic enzymes.
Note: High target overlap does not imply identical mechanism or therapeutic equivalence. Binding affinity, tissue distribution, bioavailability, and downstream signaling differ significantly between compounds even when they bind the same protein.
Frequently Asked Questions
What do darapladib and same have in common?
darapladib and same share 2 molecular targets with a Jaccard similarity of 9%. Both bind overlapping sets of proteins based on BindingDB and ChEMBL binding affinity data.
Can darapladib and same be combined?
darapladib and same share 2 molecular targets, suggesting potential pathway overlap. Combination use should be evaluated with a qualified healthcare professional. BiohacksAI does not provide medical advice.
Which has more research: darapladib or same?
Both darapladib and same have substantial PubMed research. View their individual profiles for full evidence scores.